Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchProxalutamideProxalutamide (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Proxalutamide for COVID-19
4 studies from 38 scientists
1,953 patients in 2 countries
Statistically significant lower risk for mortality, ventilation, hospitalization, recovery, and viral clearance.
4 studies from 2 independent teams in 2 countries show statistically significant improvements.
COVID-19 Proxalutamide studies. Mar 2024. c19early.org
0 0.5 1 1.5+ All studies 78% Mortality 78% Hospitalization 72% Viral clearance 74% RCTs 78% RCT mortality 78% Early 71% Late 78% Favorsproxalutamide Favorscontrol
Recent:
Zheng.
Proxalutamide has been officially adopted in all or part of 3 countries. Submit updates/corrections.
Mar 3
Covid Analysis Proxalutamide for COVID-19: real-time meta analysis of 4 studies
Statistically significant lower risk is seen for mortality, ventilation, hospitalization, recovery, and viral clearance. 4 studies from 2 independent teams in 2 countries show statistically significant improvements. Meta analysis using th..
Jan 18
Zheng et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2024.107096 Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis
Systematic review and network meta-analysis of 160 studies involving over 900,000 COVID-19 patients assessing the efficacy and safety of small-molecule antivirals. For proxalutamide, significant benefits were found for mortality, mechanic..
Jul 17
2023
Qiao et al., PNAS, doi:10.1073/pnas.222180912 Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response
In Vitro study showing dose-dependent inhibition of multiple SARS-CoV-2 variants with proxalutamide. Authors find that proxalutamide increased levels of NRF2 and decreased lung inflammation. Authors conclude that there is compelling evide..
Jun 9
2022
Cadegiani, F. Frontiers Fraudulent Retraction
Details on the censorship of [McCoy].
Apr 8
2022
Ma et al., AACR Annual Meeting 2022 Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients
Review of the mechanisms of action of proxalutamide for COVID-19, and In Vitro results showing that proxalutamide inhibited SARS-CoV-2 wild type, alpha and delta variants, with IC50 of 69, 48 and 39nM. Only the abstract is currently avail..
Apr 5
2022
Kintor, Press Release Kintor Pharma's Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
50% lower hospitalization (p=0.38) and 74% improved viral clearance (p=0.0001). RCT 733 outpatients, 99% in the USA, showing lower hospitalization/death, and significantly reduced viral load with proxalutamide treatment. The viral clearance result is from .
Dec 27
2021
Kintor, News Releease Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19
News release reporting on interim analysis of NCT04870606, showing that statistical criteria were not met, there was a very low event rate, and that Kintor plans to amend the protocol and continue to enroll higher risk patients.
Dec 25
2021
Cadegiani et al., Cureus, doi:10.7759/cureus.20691 Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
78% lower mortality (p<0.0001), 45% improved recovery (p<0.0001), and 33% shorter hospitalization (p=0.0001). RCT 778 hospitalized patients in Brazil, 423 treated with proxalutamide, showing significantly lower mortality and improved recovery with treatment. NCT04728802 and NCT05126628. Authors note that cases in this trial were predominantly the..
Dec 17
2021
Kintor, News Comments 开拓药业普克鲁胺治疗新冠预计本月发布临床数据
News report noting that real-world results for proxalutamide in Paraguay show significantly lower mortality and are consistent with the results of previous studies in Brazil.
Jul 25
2021
Cadegiani et al., medRxiv, doi:10.1101/2021.07.24.21261047 Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
Analysis of data from two proxalutamide early treatment RCTs with 445 patients showing substantial improvements in immunologic, inflammatory, thrombotic, and oxygen markers, which may support the observed reduction in hospitalization.
Jul 16
2021
Kintor Pharmaceutical, Press Release Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
News release announcing that proxalutamide has been granted an emergency use authorization for COVID-19 in Paraguay.
Jul 10
2021
Cadegiani et al., medRxiv, doi:10.1101/2021.07.06.21260086 Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
90% lower ventilation (p=0.07) and 86% lower hospitalization (p=0.0008). RCT 177 women in Brazil, 75 treated with proxalutamide, showing significantly lower hospitalization with treatment.
Jul 2
2021
Zimerman et al., medRxiv, doi:10.1101/2021.06.28.21259661 Proxalutamide (GT0918) Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration - an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
Analysis of treatment duration in the Proxa-Rescue AndroCoV trial showing significantly higher mortality among patients that interrupted treatment with proxalutamide. NCT04728802.
Jul 1
2021
Medeiros et al., ResearchGate Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial
Analysis of radiological findings from the Proxa-Rescue AndroCoV trial showing that proxalutamide significantly improves lung opacities compared to placebo. NCT04728802.
Feb 22
2021
Cadegiani et al., Cureus, doi:10.7759/cureus.13492 Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
92% improved viral clearance (p<0.0001) and 77% improved recovery (p<0.0001). RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery. Third party analysis suggests potential randomization failure: [steamtraen.blogspot.com].
Dec 30
2020
McCoy et al., Frontiers in Medicine, doi:10.3389/fmed.2021.668698 (date from preprint) Proxalutamide (GT0918) Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
97% lower ventilation (p<0.0001) and 91% lower hospitalization (p<0.0001). RCT 268 male patients in Brazil, 134 treated with proxalutamide, showing significantly lower hospitalization and mechanical ventilation. NCT04446429. This paper was censored without details or author response, and the editors have ignored..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit